Trial Profile
A phase II, randomized, double-blind, placebo-controlled, parallel-group study of daclizumab in patients With chronic, persistent asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2009
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors PDL BioPharma
- 15 Nov 2008 Primary endpoint 'Forced expiratory volume in 1 second' has been met.
- 10 Sep 2007 Status changed from in progress to completed.
- 27 Mar 2006 New trial record.